alpha-cannabis Pharma Revenue

Pharmaceutical Manufacturing • Auetal, Lower Saxony, Germany • 1-10 Employees

alpha-cannabis Pharma revenue & valuation

Annual revenue	$427,775
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$1,400,000
Total funding	No funding

Key Contact at alpha-cannabis Pharma

Alexander Klomsdorff

Chief Executive Officer

Company overview

Headquarters	Sandstr. A 5, Auetal, 31749, de
Phone number	+495752
Website	alpha-cannabis.de
NAICS	3254
Keywords	Medical Cannabis, Cannabinoids, Medizinisches Cannabis, Cannabis Analytics, Api (Active Pharmaceutical Ingredients), Cannabinoid Analytik, Cannabinoide In Der Medizin, Wirkstoffherstellung
Founded	2016
Employees	1-10

alpha-cannabis Pharma Email Formats

alpha-cannabis Pharma uses 1 email format. The most common is {last name} (e.g., doe@alpha-cannabis.de), used 100% of the time.

Format	Example	Percentage
{last name}	doe@alpha-cannabis.de	100%

About alpha-cannabis Pharma

alpha-cannabis® Pharma GmbH has been developing, producing and supplying monograph-compliant, cannabis-based active pharmaceutical ingredients (API) for therapeutic use since 2016. These medicinal substances are intended exclusively for the production of prescription drugs according to a doctor's prescription. As a license holder for the sale of narcotics in accordance with § 3 BtMG and EUDRA-listed manufacturer of GMP-compliant cannabis-based medicinal substances, our company is subject to supervision by the BfArM (Federal Institute for Drugs and Medical Devices) and the state trade supervisory office. Thanks to our own analytical facilities and state-of-the-art processing equipment, we are able to reliably supply all active ingredients for the entire range of cannabis-based medicinal products. Hospitals, clinics, pharmacies and the pharmaceutical industry have been among our satisfied customers for many years. alpha-cannabis® branded products are available from pharmaceutical wholesalers or directly from us. Seit 2016 entwickelt, produziert und liefert alpha-cannabis® Pharma GmbH Monographie-konforme, Cannabis-basierte Wirkstoffe (API) für den therapeutischen Einsatz. Diese Arzneistoffe sind ausschließlich zur Herstellung von Rezepturarzneimitteln nach ärztlicher Verordnung bestimmt. Als Erlaubnisinhaber für den Verkehr mit Betäubungsmitteln gem. § 3 BtMG und EUDRA gelisteter Hersteller GMP-konformer Cannabis-basierter Arzneistoffe unterliegt unser Unternehmen der Aufsicht durch das BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) und durch das staatliche Gewerbeaufsichtsamt. Durch eigene Analytik und die Ausstattung mit modernsten verfahrenstechnischen Anlagen sind wir in der Lage, alle Wirkstoffe für die gesamte Palette an Cannabisarzneimitteln zuverlässig bereitstellen zu können. Krankenhäuser, Kliniken, Apotheken und die pharmazeutische Industrie zählen seit Jahren zu unseren zufriedenen Kunden.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

alpha-cannabis Pharma has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

alpha-cannabis Pharma has never raised funding before.

Frequently asked questions

alpha-cannabis Pharma is located in Auetal, Lower Saxony, DE.

You can reach alpha-cannabis Pharma at +495752.

alpha-cannabis Pharma generates an estimated annual revenue of $427,775. This revenue figure reflects the company's market position and business performance in its industry.

alpha-cannabis Pharma has an estimated valuation of $1,400,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

alpha-cannabis Pharma was founded in 2016, making it 10 years old. The company has established itself as a significant player in its industry over this time.

alpha-cannabis Pharma has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at alpha-cannabis Pharma

Alexander Klomsdorff

Chief Executive Officer

4.8

40,000 users